A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates

被引:10
作者
Jellinger, RM [1 ]
Shafer, RW [1 ]
Merigan, TC [1 ]
机构
[1] STANFORD UNIV,MED CTR,DIV INFECT DIS & GEOG MED,STANFORD,CA 94305
基金
英国医学研究理事会;
关键词
D O I
10.1093/infdis/175.3.561
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human immunodeficiency virus type 1 (HIV-1) drug susceptibility testing is often curtailed because such testing is expensive and time consuming. A colorimetric tetrazolium dye method previously used for high-throughput antiviral drug screening was adapted to assess the susceptibility of 16 HIV-1 isolates to zidovudine, didanosine, lamivudine, and nevirapine in MT-2 cells. Cell viability was assessed colorimetrically, and all measurements and calculations were automated. Each HIV-1 isolate was tested in greater than or equal to 5 assays to determine the reproducibility of the assay in HIV-1 isolates with known reverse-transcriptase mutations. The drug susceptibility of several mutant HIV-1 strains whose drug susceptibilities had not previously been well defined was also determined. Data on HIV-1 replication from the susceptibility assays indicated that some mutant HIV-1 isolates may have been less cytopathic in MT-2 cells than wild type HIV-1 isolates.
引用
收藏
页码:561 / 566
页数:6
相关论文
共 22 条
[1]   Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay [J].
Boucher, CAB ;
Keulen, W ;
vanBommel, T ;
Nijhuis, M ;
DeJong, D ;
DeJong, MD ;
Schipper, P ;
Back, NKT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2404-2409
[2]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[3]   RESISTANCE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TO ANTIRETROVIRAL AGENTS - A REVIEW [J].
ERICE, A ;
BALFOUR, HH .
CLINICAL INFECTIOUS DISEASES, 1994, 18 (02) :149-156
[4]   Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility [J].
Harrigan, PR ;
Kinghorn, I ;
Bloor, S ;
Kemp, SD ;
Najera, I ;
Kohli, A ;
Larder, BA .
JOURNAL OF VIROLOGY, 1996, 70 (09) :5930-5934
[5]   HIGH-DOSE NEVIRAPINE - SAFETY, PHARMACOKINETICS, AND ANTIVIRAL EFFECT IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
HAVLIR, D ;
CHEESEMAN, SH ;
MCLAUGHLIN, M ;
MURPHY, R ;
ERICE, A ;
SPECTOR, SA ;
GREENOUGH, TC ;
SULLIVAN, JL ;
HALL, D ;
MYERS, M ;
LAMSON, M ;
RICHMAN, DD .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (03) :537-545
[6]  
IVERSEN AKN, 1996, J VIROL, V70, P1076
[7]   STANDARDIZED PERIPHERAL-BLOOD MONONUCLEAR CELL-CULTURE ASSAY FOR DETERMINATION OF DRUG SUSCEPTIBILITIES OF CLINICAL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES [J].
JAPOUR, AJ ;
MAYERS, DL ;
JOHNSON, VA ;
KURITZKES, DR ;
BECKETT, LA ;
ARDUINO, JM ;
LANE, J ;
BLACK, RJ ;
REICHELDERFER, PS ;
DAQUILA, RT ;
CRUMPACKER, CS ;
BALFOUR, H ;
ERICE, A ;
COOMBS, R ;
KATZENSTEIN, D ;
LATHEY, J ;
RICHMAN, D ;
MCINTOSH, K ;
RANGAN, S ;
REICHMAN, R ;
SCOTT, W ;
USSERY, M ;
ABRAMS, L ;
MCCUTCHAN, F ;
BURKE, D ;
GARDNER, L ;
ROBERTS, C ;
CHUNG, R ;
HICKS, C ;
SHELLIE, E ;
FOWLER, A ;
MERRITT, L ;
FUJIMURAJUSTICE, M ;
RUIZ, N ;
WAGNER, K ;
GAIL, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1095-1101
[8]   5TH MUTATION IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE CONTRIBUTES TO THE DEVELOPMENT OF HIGH-LEVEL RESISTANCE TO ZIDOVUDINE [J].
KELLAM, P ;
BOUCHER, CAB ;
LARDER, BA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (05) :1934-1938
[9]   RECOMBINANT VIRUS ASSAY - A RAPID, PHENOTYPIC ASSAY FOR ASSESSMENT OF DRUG SUSCEPTIBILITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES [J].
KELLAM, P ;
LARDER, BA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (01) :23-30
[10]   Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy [J].
Larder, BA ;
Kohli, A ;
Bloor, S ;
Kemp, SD ;
Harrigan, PR ;
Schooley, RT ;
Lange, JMA ;
Pennington, KN ;
StClair, MH .
JOURNAL OF VIROLOGY, 1996, 70 (09) :5922-5929